Diagnostic value of P63 in differentiating normal gestation from molar pregnancy

Journal of Research in Medical Sciences

Volumn 18, Issue 6, 2013, Pages 462-466

  Heidarpour, Mitra ^a   Khanahmadi, Marzieh ^a  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Complete hydatidiform mole; P63; Partial hydatidiform mole; Pregnancy; Trophoblastic disease

Indexed keywords

PROTEIN P63;

ARTICLE; COMPLETE HYDATIDIFORM MOLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DESCRIPTIVE RESEARCH; DIAGNOSTIC VALUE; FEMALE; HUMAN; HUMAN TISSUE; HYDATIDIFORM MOLE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; PARTIAL HYDATIDIFORM MOLE; PREGNANCY; PROTEIN EXPRESSION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

EID: 84881156615     PISSN: 17351995     EISSN: 17357136     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Lurain JR. Gestational trophoblastic disease I: Epidemiology, pathology, clinical presentation and diagnosis of gestational trophoblastic disease, and management of hydatidiform mole. Am J Obstet Gynecol 2010;203:531-9.
2. Szulman AE, Surti U. The syndromes of hydatidiform mole. I. Cytogenetic and morphologic correlations. Am J Obstet Gynecol 1978;131:665-71.
3. Atrash HK, Hogue CJ, Grimes DA. Epidemiology of hydatidiform mole during early gestation. Am J Obstet Gynecol 1986;154:906-9.
4. Smith HO. Gestational trophoblastic disease epidemiology and trends. Clin Obstet Gynecol 2003;46:541-56.
5. Berkowitz RS, Goldstein DP. Current management of gestational trophoblastic diseases. Gynecol Oncol 2009;112:654-62.
6. Howat AJ, Beck S, Fox H, Harris SC, Hill AS, Nicholson CM, et al. Can histopathologists reliably diagnose molar pregnancy? J Clin Pathol 1993;46:599-602.
7. Fukunaga M, Katabuchi H, Nagasaka T, Mikami Y, Minamiguchi S, Lage JM. Interobserver and intraobserver variability in the diagnosis of hydatidiform mole. Am J Surg Pathol 2005;29:942-7.
8. McConnell TG, Murphy KM, Hafez M, Vang R, Ronnett BM. Diagnosis and subclassification of hydatidiform moles using p57 immunohistochemistry and molecular genotyping: Validation and prospective analysis in routine and consultation practice settings with development of an algorithmic approach. Am J Surg Pathol 2009;33:805-17.
9. Thaker HM, Berlin A, Tycko B, Goldstein DP, Berkowitz RS, Castrillon DH, et al. Immunohistochemistry for the imprinted gene product IPL/PHLDA2 for facilitating the differential diagnosis of complete hydatidiform mole. J Reprod Med 2004;49:630-6.
10. Sebire NJ, Lindsay I, Fisher RA. Recent advances in gestational trophoblastic neoplasia. Curr Diagn Pathol 2007;13:210-21.
11. Castrillon DH, Sun D, Weremowicz S, Fisher RA, Crum CP, Genest DR. Discrimination of complete hydatidiform mole from its mimics by immunohistochemistry of the paternally imprinted gene product p57KIP2. Am J Surg Pathol 2001;25:1225-30.
12. Chiu PM, Ngan YS, Khoo US, Cheung AN. Apoptotic activity in gestational trophoblastic disease correlates with clinical outcome: Assessment by the caspase-related M30 CytoDeath antibody. Histopathology 2001;38:243-9.
13. Chen Y, Shen D, Gu Y, Zhong P, Xie J, Song Q. The diagnostic value of Ki-67, P53 and P63 in distinguishing partial hydatidiform mole from hydropic abortion. Wien Klin Wochenschr 2012;124:184-7.
14. Zhang HJ, Xue WC, Siu MK, Liao XY, Ngan HY, Cheung AN. P63 expression in gestational trophoblastic disease: Correlation with proliferation and apoptotic dynamics. Int J Gynecol Pathol 2009;28:172-8.
15. Erfanian M, Sharifi N, Omidi AA. P63 and Ki-67 expression in trophoblastic disease and spontaneous abortion. J Res Med Sci 2009;14:375-84.
16. Ramalho LN, Maggiori MS, Ribeiro-Silva A, Peres LC. P63 expression in hydropic abortion and gestational trophoblastic diseases. Placenta 2006;27:740-3.
17. Moll UM. The role of p63 and p73 in tumor formation and progression: Coming of age toward clinical usefulness. Clin Cancer Res 2003;9:5437-41.
18. Yang A, Kaghad M, Wang Y, Gillett E, Fleming MD, Dötsch V, et al. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell 1998;2:305-16.
19. Genest DR. Partial hydatidiform mole: Clinicopathological features, differential diagnosis, ploidy and molecular studies, and gold standards for diagnosis. Int J Gynecol Pathol 2001;20:315-22.
20. Dietz S, Rother K, Bamberger C, Schmale H, Mössner J, Engeland K. Differential regulation of transcription and induction of programmed cell death by human p53-family members p63 and p73. FEBS Lett 2002;525:93-9.
21. Vincek V, Knowles J, Li J, Nassiri M. Expression of p63 mRNA isoforms in normal human tissue. Anticancer Res 2003;23:3945-8.
22. Lee Y, Kim KR, McKeon F, Yang A, Boyd TK, Crum CP, et al. A unifying concept of trophoblastic differentiation and malignancy defined by biomarker expression. Hum Pathol 2007;38:1003-13.